NEW YORK (GenomeWeb) – Qiagen said this week that a judge has recommended partial dismissal of lawsuit filed against the company by Oxford Immunotec for patent infringement. The suit, filed in August 2015, concerns six patents and Qiagen's QuantiFERON Gold latent TB test. Oxford Immunotec alleged that Qiagen and other companies had infringed on its patents by developing their own TB tests. A magistrate judge has now recommended that part of the case against the defendants be dismissed as part of Oxford Immunotec's patents covered unpatentable subject matter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.